Fav of CanadaFav of Canada
  • Home
  • News
  • Money
  • Living
  • Entertainment
  • Health
  • Sci-Tech
  • Travel
  • More
    • Sports
    • Web Stories
    • Global
    • Press Release

Subscribe to Updates

Get the latest Canada's trends and updates directly to your inbox.

What's On

‘Bomb threats’ made at multiple Canadian airports as police investigate

July 3, 2025

Is this the easiest it’s been in 3 years to own a home?

July 3, 2025

Home insurance rates need more transparency from Ontario regulator: complaint

July 3, 2025
Facebook X (Twitter) Instagram
Fav of CanadaFav of Canada
  • Home
  • News
  • Money
  • Living
  • Entertainment
  • Health
  • Sci-Tech
  • Travel
  • More
    • Sports
    • Web Stories
    • Global
    • Press Release
Fav of CanadaFav of Canada
You are at:Home » Ozempic, Wegovy linked to rare cases of eye disorder, EMA says
Health

Ozempic, Wegovy linked to rare cases of eye disorder, EMA says

By favofcanada.caJune 6, 2025No Comments2 Mins Read
Facebook Twitter Pinterest Telegram WhatsApp Email Tumblr LinkedIn
Share
Facebook Twitter Pinterest WhatsApp Email

The European Medicines Agency’s safety committee has concluded that the use of Novo Nordisk’s popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye condition.

Called non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo’s diabetes drugs Ozempic and Rybelsus, the regulator said on Friday.

The EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine.

NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after glaucoma.

Studies have linked semaglutide to NAION in the past. But this is the first time a regulator has made the link.

Receive the latest medical news and health information delivered to you every Sunday.

Get weekly health news

Receive the latest medical news and health information delivered to you every Sunday.

Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness.

A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other classes.

The EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and post-marketing surveillance.

It has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of “very rare.”

The U.S. Food and Drug Administration did not immediately respond to a Reuters request for comment.


Related Articles

Is VISP an independent administrator? Here’s what some documents say

By favofcanada.caJuly 3, 2025

Canada set up a $50M vaccine injury. Those harmed say it’s failing them – National

By favofcanada.caJuly 2, 2025

Oxaro statement: Consulting firm ‘continues to adapt’ approach to VISP

By favofcanada.caJuly 2, 2025

Canada set up a $50M vaccine injury program. Those harmed say it’s failing them. – National

By favofcanada.caJuly 2, 2025

Climate change driving rise in tick-borne illnesses such as Lyme disease

By favofcanada.caJune 28, 2025

WHO still seeking COVID-19 origin, says all scenarios ‘remain on the table’

By favofcanada.caJune 27, 2025
Add A Comment

Leave A Reply Cancel Reply

Don't Miss

Is this the easiest it’s been in 3 years to own a home?

By favofcanada.caJuly 3, 2025

After three years of a hot housing market, full of bidding wars and homes selling…

Home insurance rates need more transparency from Ontario regulator: complaint

July 3, 2025

Is VISP an independent administrator? Here’s what some documents say

July 3, 2025

‘Nothing Was Ready’: Inside Canada’s Vaccine Injury Support Program – National

July 3, 2025
Stay In Touch
  • Facebook
  • Twitter
  • Pinterest
  • Instagram
  • YouTube
  • Vimeo
Our Picks

MMF to display ‘Our Grandmothers’ collection of historical and cultural Métis items

By favofcanada.caJuly 3, 2025

Blue Jays continue ascent, tied atop AL East

By favofcanada.caJuly 3, 2025

Just for Laughs founder Gilbert Rozon says he is a target of #MeToo movement

By favofcanada.caJuly 2, 2025
About Us
About Us

Fav of Canada is your one-stop website for the latest Canada's trends and updates, follow us now to get the news that matters to you.

We're accepting new partnerships right now.

Email Us: [email protected]
Contact: +44 7741 486006

Our Picks

‘Bomb threats’ made at multiple Canadian airports as police investigate

July 3, 2025

Is this the easiest it’s been in 3 years to own a home?

July 3, 2025

Home insurance rates need more transparency from Ontario regulator: complaint

July 3, 2025

Subscribe to Updates

Get the latest Canada's trends and updates directly to your inbox.

Facebook X (Twitter) Instagram Pinterest TikTok
  • Privacy Policy
  • Terms of use
  • Advertise
  • Contact
© 2025 Fav of Canada. All Rights Reserved.

Type above and press Enter to search. Press Esc to cancel.